STOCK TITAN
  1. Home
  2. News
  3. APLS

Apellis Pharmaceuticals Inc - APLS STOCK NEWS

Welcome to our dedicated news page for Apellis Pharmaceuticals (Ticker: APLS), a resource for investors and traders seeking the latest updates and insights on Apellis Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Apellis Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Apellis Pharmaceuticals's position in the market.

News
Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
Rhea-AI Summary
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) reports approximately $138 million in preliminary U.S. net product revenues for the fourth quarter of 2023, with strong sales of SYFOVRE® and EMPAVELI®. SYFOVRE® garnered approximately $114 million, and EMPAVELI® contributed approximately $24 million. The company also highlighted high patient compliance rates and increased use of the EMPAVELI Injector. These results were presented at the 42nd Annual J.P. Morgan Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.66%
Tags
none
-
News
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) approved the grant of equity awards to 2 new employees as equity inducement awards outside of the company's 2017 Stock Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). Each employee received 1,960 restricted stock units (RSUs) that will vest annually over a 4-year period, subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.36%
Tags
conferences
News
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference
Rhea-AI Summary
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) will host a fireside chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4, 2023, at 2:25 p.m. ET. The event will be available via a live webcast and a replay will be available for approximately 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
conferences
-
News
Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union
Rhea-AI Summary
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) received a negative trend vote from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) regarding its marketing authorization application (MAA) for intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The company plans to appeal the outcome and seek re-examination of the opinion after the CHMP adopts a negative opinion at its next meeting in January 2024. The MAA is based on results from the Phase 3 OAKS and DERBY studies at 24 months, which showed promising treatment effects and a well-demonstrated safety profile. However, the negative trend vote has led to disappointment among company executives and the retina community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.02%
Tags
none
-
News
EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting
Rhea-AI Summary
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi presented post hoc data at the American Society of Hematology (ASH) Annual Meeting, reinforcing the long-term efficacy and safety of EMPAVELI® (pegcetacoplan) in adults with paroxysmal nocturnal hemoglobinuria (PNH) for up to three years. Key markers of disease rapidly improved and were sustained, with the majority of patients remaining transfusion free over the long term. No cases of meningococcal infection were observed over three years in the analysis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.54%
Tags
none
News
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) granted equity awards to 4 new employees, totaling 5,855 restricted stock units (RSUs) under the 2020 Inducement Stock Incentive Plan, subject to vesting conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
none
-
News
Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference
Rhea-AI Summary
Apellis Pharmaceuticals to host fireside chat at 6th Annual Evercore ISI HealthCONx Conference (Nasdaq: APLS)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
conferences
-
News
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Apellis Pharmaceuticals approves grant of equity awards to 20 new employees, with each employee receiving 28,465 restricted stock units (RSUs). The RSUs will vest annually over a four-year period, subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.07%
Tags
none
News
SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)
Rhea-AI Summary
Apellis Pharmaceuticals announces positive data from the GALE extension study of SYFOVRE, the FDA-approved treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). In Year 3, SYFOVRE reduced nonsubfoveal GA lesion growth by over 40% compared to projected sham. The study demonstrated robust long-term compliance with 92% of patients completing the first year. The data were presented at the American Academy of Ophthalmology Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock APLS logo
Apellis Pharmaceuticals Inc

Nasdaq:APLS

APLS Rankings

#1112 Ranked by Market Cap
#3412 Ranked by Stock Gains
N/A Ranked by Dividends

APLS Stock Data

6.25B
81.04M
13.24%
95.98%
8.66%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Waltham

About APLS

apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.